Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Research & Development (2022 - 2025)

Corvus Pharmaceuticals has reported Research & Development over the past 4 years, most recently at $9.9 million for Q4 2025.

  • Quarterly results put Research & Development at $9.9 million for Q4 2025, up 66.37% from a year ago — trailing twelve months through Dec 2025 was $33.7 million (up 73.94% YoY), and the annual figure for FY2025 was $33.7 million, up 73.94%.
  • Research & Development for Q4 2025 was $9.9 million at Corvus Pharmaceuticals, up from $8.5 million in the prior quarter.
  • Over the last five years, Research & Development for CRVS hit a ceiling of $10.4 million in Q3 2022 and a floor of $4.0 million in Q3 2023.
  • Median Research & Development over the past 4 years was $5.0 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Research & Development: tumbled 61.75% in 2023 and later skyrocketed 91.37% in 2025.
  • Corvus Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then decreased by 1.99% to $4.0 million in 2023, then surged by 49.39% to $6.0 million in 2024, then skyrocketed by 66.37% to $9.9 million in 2025.
  • The last three reported values for Research & Development were $9.9 million (Q4 2025), $8.5 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.